NanoStilbene

a nanoparticle formulation of pterostilbene

NanoStilbene PK Study

NanoStilbene Administration Results in Superior Pharmacokinetic Profi­le Compared to Pterostilbene Administration

NanoStilbene Clinical Trial in Cancer

These results suggest that NanoStilbene may be a useful adjuvant to immunotherapy of cancer rescuing T cell and NK cell activities.

Pterostilbene Literature Review

Cancer and Pterostilbene Comprehensive Literature Review

NanoStilbene™ In The News

NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer

Recent Data Supports Investigation of Commercially Available Product as an Adjuvant to Chemotherapy for Cancer

OCEANSIDE, Calif., July 29, 2019 (GLOBE NEWSWIRE) — NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) reported today positive animal data demonstrating synergy at suppressing growth of cancer cells between its commercially available NanoStilbene™ nutraceutical product[1] together with cyclophosphamide, a type of chemotherapy. The data indicate that NanoStilbene™, a proprietary formulation of pterostilbene [2], may increase the effectiveness of drugs that kill cancer through blocking mechanistic elements of the cell division machinery.

“The dogma in oncology has been that chemotherapy efficacy is usually suppressed by agents that act as antioxidants. This is because many types of chemotherapy kill cancer cells by induction of oxidative stress. Interestingly, the recent data suggests a contradictory finding, in that NanoStilbene™, which is a proprietary formulation of the antioxidant pterostilbene, actually augments the killing ability of cyclophosphamide, a type of chemotherapy,” said Thomas Ichim, Ph.D., Board Member of TSOI and coinventor on the Company’s patents. 

NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer

Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer

Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer

Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA

Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)

Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio

NanoStilbene Enhances Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators

Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation

Therapeutic Solutions International Files Patent on Clinical Data Demonstrating Reduction of Inflammatory Cytokines Using NanoStilbene™

TSOI Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene

Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development

Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for Rapid Access to Blood-Brain Barrier

Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™

Therapeutic Solutions International Releases “IsoStilbene” Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells

Therapeutic Solutions International Releases “DermalStilbene” a Topical Formulation of Pterostilbene

Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant NanoStilbene

Therapeutic Solutions International Develops “NanoStilbene” Nanoparticle Formulation of Pterostilbene

Therapeutic Solutions International, Inc. files new patent for the Synergistic Inhibition of Glioma Using Pterostilbene

Frequently Asked Questions

Learn More About It!

What is Pterostilbene?

Pterostilbene is a natural dietary compound found in blueberries. We use the syntheic version due to limited amounts occuring naturally in the berries.

how much nanostilbene should i take daily?

We recommend up to 300mg daily which is approx 1.5 milliliters. However many find that 200mg daily is also suffice, therefore a range of 200-300mg daily is recommended.

can it be applied topically?

Yes small amounts may be applied locally but remember at 200mg per ml it is highly concentrated with a single drop containing 10mg.

What is nanostilbene?

NanoStilbene  is an easily absorbed nanoemulsion of nanoparticle pterostilbene in the range of 75-100nm at a concentration of 200 milligrams per milliliter

what is the concentration of nanostilbene?

NanoStilbene contains 200mg per ml or approximately 10mg per drop.

where can i obtain nanostilbene?

NanoStilbene can be obtained at our e-commerce site.